Impaired Vasodilation in the Pathogenesis of Hypertension: Focus on Nitric Oxide, Endothelial-Derived Hyperpolarizing Factors, and Prostaglandins

Journal of Clinical Hypertension

Volumn 14, Issue 4, 2012, Pages 198-205

  Giles, Thomas D ^a   Sander, Gary E ^a   Nossaman, Bobby D ^a,b   Kadowitz, Philip J ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ochsner Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; GLUCOSE; HYDROGEN PEROXIDE; INSULIN; N(G) METHYLARGININE; NEBIVOLOL; NITRIC OXIDE; POTASSIUM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; XANTHINE OXIDASE;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HUMAN; HYPERTENSION; IMPAIRED VASODILATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SHEAR STRESS; VASCULAR DISEASE; VASODILATATION;

BIOLOGICAL FACTORS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS; POTASSIUM CHANNELS; PROSTAGLANDINS; VASODILATION;

EID: 84859332979     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00606.x     Document Type: Article

References (120)

1. Furchgott R, Vanhoutte P. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-2018.
2. Bevan JA, Henrion D. Pharmacological implications of the flow-dependence of vascular smooth muscle tone. Annu Rev Pharmacol Toxicol. 1994;34:173-190.
3. Sainz JM, Reche C, Rabano MA, et al. Effects of nitric oxide on aldosterone synthesis and nitric oxide synthase activity in glomerulosa cells from bovine adrenal gland. Endocrine. 2004;24:61-71.
4. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol. 1997;79:3-8.
5. Moncada S. The L-arginine: nitric oxide pathway, cellular transduction and immunological roles. Adv Second Messenger Phosphoprotein Res. 1993;28:97-99.
6. Cylwik D, Mogielnicki A, Buczko W. L-arginine and cardiovascular system. Pharmacol Rep. 2005;57:14-22.
7. Mayer B, Heinzel B, Klatt P, et al. Nitric oxide synthase-catalyzed activation of oxygen and reduction of cytochromes: reaction mechanisms and possible physiological implications. J Cardiovasc Pharmacol. 1992;20(Suppl 12):S54-S56.
8. Smith GC, Tew DG, Wolf CR. Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci USA. 1994;91:8710-8714.
9. Li J, Zhou Z, Jiang DJ, et al. Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine. Clin Exp Hypertens. 2007;29:489-501.
10. Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. 2005;10(Suppl 1):S19-S25.
11. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
12. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37:767-773.
13. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension. 2004;44:112-116.
14. Paulus WJ, Bronzwaer JG. Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol. 2004;287:H8-H13.
15. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104:1286-1291.
16. Spieker LE, Flammer AJ, Luscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol. 2006;(176 pt 2)::249-283.
17. Cebeci SA, Kocaturk PA, Kavas GO. Hypertension: does impaired endothelium-dependent relaxation affect superoxide scavenging? Biol Trace Elem Res. 2002;90:239-249.
18. Taddei S, Virdis A, Ghiadoni L, et al. Endothelial dysfunction in hypertension. J Nephrol. 2000;13:205-210.
19. Fitzgerald SM, Brands MW. Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab. 2000;279:E762-E768.
20. Haynes WG, Noon JP, Walker BR, et al. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens. 1993;11:1375-1380.
21. Félétou M, Vanhoutte PM. EDHF: an update. Clin Sci (Lond). 2009;117:139-155.
22. Félétou M, Köhler R, Vanhoutte PM. Endothelium derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Current Rev Hypertens. 2010;12:267-275.
23. Edwards G, Feletou M, Weston AH. Endothelium-derived hyperpolarizing factors and associated pathways: a synopsis. Pflugers Arch. 2010;459:863-879.
24. Köhler R, Kaistha BP, Wulff H. Vascular Kca-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets. 2010;14:143-155.
25. Brähler S, Kaistha A, Schmidt VJ, et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 2009;119:2323-2332.
26. Wei CM, Hu S, Miller VM, et al. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun. 1994;205:765-771.
27. Honing ML, Smits P, Morrison PJ, et al. C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension. 2001;37:1179-1183.
28. Ahluwalia A, Hobbs AJ. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci. 2005;26:162-167.
29. Sandow SL, Tare M. C-type natriuretic peptide: a new endothelium-derived hyperpolarizing factor? Trends Pharmacol Sci. 2007;28:61-67.
30. 2S be the third endogenous gaseous transmitter? FASEB J. 2002;16:1792-1798.
31. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917-935.
32. 2S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001;20:6008-6016.
33. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc. 1979;38:66-71.
34. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587-590.
35. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med. 2002;7:195-202.
36. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev. 2005;57:585-630.
37. Chen YH, Yet SF, Perrella MA. Role of heme oxygenase-1 in the regulation of blood pressure and cardiac function. Exp Biol Med (Maywood). 2003;228:447-453.
38. Wang R, Shamloul R, Wang X, et al. Sustained normalization of high blood pressure in spontaneously hypertensive rats by implanted hemin pump. Hypertension. 2006;48:685-692.
39. Ellis A, Triggle CR. Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol Pharmacol. 2003;81:1013-1028.
40. Lucchesi PA, Belmadani S, Matrougui K. Hydrogen peroxide acts as both vasodilator and vasoconstrictor in the control of perfused mouse mesenteric resistance arteries. J Hypertens. 2005;23:571-579.
41. Edwards DH, Li Y, Griffith TM. Hydrogen peroxide potentiates the EDHF phenomenon by promoting endothelial Ca2+ mobilization. Arterioscler Thromb Vasc Biol. 2008;28:1774-1781.
42. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521-1530.
43. Matoba T, Shimokawa H, Kubota H, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002;290:909-913.
44. Miura H, Bosnjak JJ, Ning G, et al. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res. 2003;92:e31-e40.
45. Matoba T, Shimokawa H. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. J Pharmacol Sci. 2003;92:1-6.
46. Garry A, Edwards DH, Fallis IF, et al. Ascorbic acid and tetrahydrobiopterin potentiate the EDHF phenomenon by generating hydrogen peroxide. Cardiovasc Res. 2009;84:218-226.
47. Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pharmacol Res. 2004;49:543-549.
48. Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
49. Weston AH, Félétou M, Vanhoutte PM, et al. Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol. 2005;145:775-784.
50. Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11, 12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation. 2003;107:769-776.
51. Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
52. Edwards G, Thollon C, Gardener MJ, et al. Role of gap junctions and EETs in endothelium-dependent hyperpolarization of porcine coronary artery. Br J Pharmacol. 2000;129:1145-1154.
53. Greenberg S, Kadowitz PJ. Difference in prostaglandin modulation of arterial and venous smooth muscle responses to bradykinin and norepinephrine. Methods Find Exp Clin Pharmacol. 1982;4:7-24.
54. Chapple DJ, Dusting GJ, Hughes R, et al. Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and prostaglandin E2 in anaesthetized dogs. Br J Pharmacol. 1980;68:437-447.
55. Lippton HL, Paustian PW, Mellion BT, et al. Cardiovascular actions of prostacyclin (PGI2) in the cat. Arch Int Pharmacodyn Ther. 1979;241:121-130.
56. de Kergommeaux BD, Ali M, McDonald JW. Effects of ASA on thromboxane and prostacyclin synthesis by rabbit aorta and pulmonary artery. Prostaglandins Leukot Med. 1983;11:225-231.
57. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
58. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
59. Peach MJ, Loeb AL. Changes in vascular endothelium and its function in systemic arterial hypertension. Am J Cardiol. 1987;60:110I-115I.
60. Minuz P, Barrow SE, Cockcroft JR, et al. Prostacyclin and thromboxane biosynthesis in mild essential hypertension. Hypertension. 1990;15:469-474.
61. Gluais P, Lonchampt M, Morrow JD, et al. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol. 2005;146:834-845.
62. Gluais P, Paysant J, Badier-Commander C, et al. In SHR aorta, calcium ionophore A-23187 releases prostacyclin and thromboxane A2 as endothelium-derived contracting factors. Am J Physiol Heart Circ Physiol. 2006;291:H2255-H2264.
63. Williams SP, Dorn GW 2nd, Rapoport RM. Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle. Am J Physiol. 1994;267:H796-H803.
64. Panza JA, Quyyumi AA, Brush JE Jr, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
65. Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
66. Raij L. Nitric oxide in the pathogenesis of cardiac disease. J Clin Hypertens. 2006;8:30-39.
67. Giles TD. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens. 2006;8:2-16.
68. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol. 2004;20(Suppl B):7B-15B.
69. Nakamura R, Egashira K, Arimura K, et al. Increased inactivation of nitric oxide is involved in impaired coronary flow reserve in heart failure. Am J Physiol Heart Circ Physiol. 2001;281:H2619-H2625.
70. Champion HC, Bivalacqua TJ, Greenberg SS, et al. Adenoviral gene transfer of endothelial nitric-oxide synthase (Enos) partially restores normal pulmonary arterial pressure in Enos-deficient mice. Proc Natl Acad Sci USA. 2002;99:13248-13253.
71. Fichtlscherer S, Breuer S, Schachinger V, et al. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J. 2004;25:1412-1418.
72. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-246.
73. Uppu RM, Nossaman BD, Greco AJ, et al. Cardiovascular effects of peroxynitrite. Clin Exp Pharmacol Physiol. 2007;34:933-937.
74. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
75. Zalba G, Beaumont FJ, San JoseG, et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension. 2000;35:1055-1061.
76. Li JJ, Chen JL. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses. 2005;64:925-929.
77. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:998-1005.
78. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des. 2002;8:155-166.
79. Wyatt AW, Steinert JR, Mann GE. Modulation of the L-arginine/nitric oxide signalling pathway in vascular endothelial cells. Biochem Soc Symp. 2004;(71):143-156.
80. Schmidt HH, Pollock JS, Nakane M, et al. Ca2+/calmodulin-regulated nitric oxide synthases. Cell Calcium. 1992;13:427-434.
81. Berka V, Yeh HC, Gao D, et al. Redox function of tetrahydrobiopterin and effect of L-arginine on oxygen binding in endothelial nitric oxide synthase. Biochemistry. 2004;43:13137-13148.
82. Perry JM, Marletta MA. Effects of transition metals on nitric oxide synthase catalysis. Proc Natl Acad Sci USA. 1998;95:11101-11106.
83. Ortiz de Montellano PR, Nishida C, Rodriguez-Crespo I, Gerber N. Nitric oxide synthase structure and electron transfer. Drug Metab Dispos. 1998;26:1185-1189.
84. Wang X, Hattori Y, Satoh H, et al. Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats. Eur J Pharmacol. 2007;555:48-53.
85. Fukuda Y, Teragawa H, Matsuda K, et al. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart. 2002;87:264-269.
86. Ueda S, Matsuoka H, Miyazaki H, et al. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol. 2000;35:71-75.
87. Leopold JA, Loscalzo J. Organic nitrate tolerance and endothelial dysfunction: role of folate therapy. Minerva Cardioangiol. 2003;51:349-359.
88. Dixon LJ, Morgan DR, Hughes SM, et al. Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation. 2003;107:1725-1728.
89. Nossaman BD, Kadowitz PJ. Potential benefits of peroxynitrite. Open Pharmacol J. 2008;2:31-53.
90. Nossaman BD, Dabisch PA, Liles JT, et al. Peroxynitrite does not impair pulmonary and systemic vascular responses. J Appl Physiol. 2004;96:455-462.
91. Nossaman BD, Bivalacqua TJ, Champion HC, et al. Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat. J Cardiovasc Pharmacol. 2007;50:358-366.
92. Ronson RS, Thourani VH, Ma XL, et al. Peroxynitrite, the breakdown product of nitric oxide, is beneficial in blood cardioplegia but injurious in crystalloid cardioplegia. Circulation. 1999;100:II384-II391.
93. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem. 1994;269:9397-9400.
94. Dowell FJ, Martin W. The effects of peroxynitrite on rat aorta: interaction with glucose and related substances. Eur J Pharmacol. 1997;338:43-53.
95. Radi R, Beckman JS, Bush KM, et al. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288:481-487.
96. Mayer B, Schrammel A, Klatt P, et al. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. Dependence on glutathione and possible role of S-nitrosation. J Biol Chem. 1995;270:17355-17360.
97. Petrie JR, Ueda S, Webb DJ, et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation. 1996;93:1331-1333.
98. Scherrer U, Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur J Endocrinol. 2000;142:315-323.
99. Lajoix AD, Reggio H, Chardes T, et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes. 2001;50:1311-1323.
100. Cleland SJ, Petrie JR, Small M, et al. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension. 2000;35:507-511.
101. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest. 1992;90:2548-2554.
102. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-E22.
103. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3:46-56.
104. Mather KJ, Lteif A, Steinberg HO, et al. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004;53:2060-2066.
105. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45:623-634.
106. Nambi V, Ballantyne C. Role of biomarkers in developing new therapies for vascular disease. World J Surg. 2007;31:676-681.
107. Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr Med Chem. 2007;14:339-351.
108. Zoppini G, Targher G, Zamboni C, et al. Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2006;16:543-549.
109. Matteucci E, Passerai S, Mariotti M, et al. Dietary habits and nutritional biomarkers in Italian type 1 diabetes families: evidence of unhealthy diet and combined-vitamin-deficient intakes. Eur J Clin Nutr. 2005;59:114-122.
110. Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag. 2005;1:55-71.
111. Miyata T, Kurokawa K. A detective story for biomedical footprints towards new therapeutic interventions in diabetic nephropathy. Intern Med. 2003;42:1165-1171.
112. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-Arginine Paradox" and acts as a novel cardiovascular risk factor. J Nutr. 2004;134:2842S-2847S.
113. Siasos G, Tousoulis D, Antoniades C, et al. L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int J Cardiol. 2007;116:300-308.
114. Winer N, Sowers JR. Diabetes and arterial stiffening. Adv Cardiol. 2007;44:245-251.
115. Shimasaki Y, Saito Y, Yoshimura M, et al. The effects of long-term smoking on endothelial nitric oxide synthase mRNA expression in human platelets as detected with real-time quantitative RT-PCR. Clin Appl Thromb Hemost. 2007;13:43-51.
116. Forgione MA, Loscalzo J. Oxidant stress as a critical determinant of endothelial function. Drug News Perspect. 2000;13:523-529.
117. Cooke JP. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin Cardiol. 1997;20:II-45-51.
118. Signorello MG, Viviani GL, Armani U, et al. Homocysteine, reactive oxygen species and nitric oxide in type 2 diabetes mellitus. Thromb Res. 2007;120:607-613.
119. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119-1121.
120. Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006;55:1133-1140.